Tag: Hospitalizations
-
Fluad for 65+ — An Enhanced Adjuvanted Flu Vaccine for Seniors
What Fluad is and who should consider it Fluad is an enhanced trivalent influenza vaccine that contains an adjuvant. In France, the Haute Autorité de Santé (HAS) recommends Fluad for people aged 65 years and older, as a preferential choice for protection against seasonal flu. The HAS considers adjuvanted vaccines like Fluad to be a…
-
Fluad: An Adjuvanted Flu Vaccine for People 65 and Older
Fluad and the Protection of Seniors (65+) Against Influenza Fluad is an enhanced adjuvanted, trivalent influenza vaccine that France’s Haute Autorité de Santé (HAS) recommends preferentially for adults aged 65 and older. In practice, HAS regards adjuvanted vaccines like Fluad as offering protection comparable to high-dose vaccines such as Efluelda, and it positions them as…
-
Dengue vaccine Qdenga reduces hospitalizations during Brazil’s 2024 outbreak
New real-world evidence from Brazil confirms Qdenga’s impact on dengue outcomes The Lancet Infectious Diseases published a pivotal study that marks the first real‑world assessment of Qdenga’s effectiveness after its approval. Conducted amid Brazil’s intense 2024 dengue surge, the observational research focused on adolescents in São Paulo, the epicenter of the outbreak, to understand how…
-
Nirsevimab sharply reduces RSV hospitalizations in U.S. infants during 2024-2025 season
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…
-
Nirsevimab Slashes RSV Hospitalizations in US Infants During 2024-2025
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated with fewer hospitalizations due to RSV. While randomized trials proved safety and efficacy, real‑world data confirm that protection extends into everyday clinical practice, easing bed occupancy and the caregiving burden…
-
Covid-19 Returns in France as XFG Frankenstein Variant Spreads
France Faces a New Covid-19 Wave as Autumn Arrives Autumn is typically a time for a renewed mix of respiratory illnesses, and France is experiencing a fresh uptick in Covid-19 activity. The Sentinelles network, which tracks acute respiratory infections in the country, reported an incidence rate of 49 cases per 100,000 inhabitants for the week…